TiumBio Co., Ltd.
TiumBio is a biopharmaceutical company developing rare-disease drug candidates NCE401, NCE403, NBP604, and TU2218.
As of 2026-10-10, TiumBio Co., Ltd. has 5 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureTiumBio was founded in 2016 and listed on KOSDAQ in 2019 as a company developing treatments for rare and intractable diseases. It is developing the small-molecule candidates NCE401 and NCE403, the biologic candidate NBP604, and TU2218, a dual TGF-β/VEGF inhibitor, while running a CDAO business through subsidiary Protium Science and a natural cosmetics OEM/ODM business through Petraon Care Lab. Petraon Care Lab, serving clients such as Ananti and Tone28, grew revenue from about KRW 3.6 billion in 2024 to about KRW 4.9 billion in 2025, and Protium Science was established in May 2021 as a dedicated CDAO company.
Products & technology
- TU2218Dual TGF-β/VEGF signaling inhibitor candidate for cancer and fibrosis
- NCE401
- NCE403
- NBP604
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2021–2023 (Phase 1/2a 1 · Phase 1 1 · Phase 1/2 1)
- Phase 1/2aTU22182023-05-22
9 trial sites
- Phase 1TU77102023-04-03
1 trial site
- Phase 1/2TU22182021-12-30
2 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Completed · 2023-08 · NCT06025552
Phase 1/2 · Recruiting · 2023-03 · NCT05784688
Phase 1/2 · Recruiting · 2021-12 · NCT05204862
Phase 2 · Completed · 2021-08 · NCT05138562
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa-transferrin fusion protein, in warfarin-pretreated healthy male participants.
Journal of thrombosis and haemostasis : JTH · 2026-04 · Kim B, Song J, Kang J 외 4
- Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist.
Clinical pharmacokinetics · 2026-03 · Bae SH, Kang J, Jeon S 외 4
- ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects.
Cancer immunology, immunotherapy : CII · 2024-08 · Kim NH, Lee J, Kim SH 외 5
- First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women.
The Journal of clinical endocrinology and metabolism · 2021-03 · Han S, Cho YS, Yoon SK 외 13
- Synthesis and biological evaluation of 3-(2-aminoethyl) uracil derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
European journal of medicinal chemistry · 2018-02 · Kim SM, Lee M, Lee SY 외 6
Patents
KIPRIS · applicant-matchedPublished · 2025-09 · Application 1020250123216
PCT · Published · 2025-09 · Application PCT/KR2025/013356
Published · 2025-04 · Application 1020250057499
PCT · Published · 2025-04 · Application PCT/KR2025/005922
Published · 2024-07 · Application 1020240089205
PCT · Published · 2024-07 · Application PCT/KR2024/009602
Withdrawn · 2024-01 · Application 1020240004841
PCT · Published · 2024-01 · Application PCT/KR2024/000558
Published · 2022-07 · Application 1020220094192
US · Published · 2022-07 · Application 18292228
Show 27 more patents
EP · Published · 2022-07 · Application 22849912.5
PCT · Published · 2022-07 · Application PCT/KR2022/011149
Withdrawn · 2022-06 · Application 1020220080860
US · Published · 2022-06 · Application 18575505
EP · Published · 2022-06 · Application 22833683.0
PCT · Published · 2022-06 · Application PCT/KR2022/009465
CN · Published · 2019-10 · Application 201980078178.9
US · Registered · 2019-10 · Application 17296836
EP · Registered · 2019-10 · Application 19889945.2
PCT · Published · 2019-10 · Application PCT/KR2019/014164
Registered · 2018-11 · Application 1020180151990
Withdrawn · 2016-08 · Application 1020160108284
JP · Registered · 2016-07 · Application 28131637
US · Registered · 2016-03 · Application 15080757
US · Registered · 2014-12 · Application 15105434
EP · Registered · 2014-12 · Application 14871697.0
Expired · 2014-02 · Application 1020140024555
EP · Registered · 2014-02 · Application 14756272.2
JP · Registered · 2014-02 · Application 27560105
Registered · 2013-12 · Application 1020130156740
JP · Registered · 2013-02 · Application 26559833
Registered · 2012-07 · Application 1020147003555
EP · Registered · 2012-07 · Application 12811865.0
EP · Registered · 2011-10 · Application 11834623.8
Expired · 2011-10 · Application 1020110106392
EP · Registered · 2011-06 · Application 11790052.2
JP · Registered · 2011-06 · Application 25513120
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive16
- OpenAIOAI-SearchBot19
- PerplexityPerplexityBot3
- AnthropicClaudeBot2
- GoogleGoogleOther1
Measured since Aug 26, 2026 · 4 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for TiumBio Co., Ltd. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition